At the 2025 Society of Surgical Oncology (SSO) Annual Meeting, Dr. Thinzar Min Lwin of City of Hope highlighted two…
Browsing: Clinical Updates
GLP-1 receptor agonists, originally developed for type 2 diabetes, are now transforming care across multiple conditions—including obesity, cardiovascular disease, neurodegenerative…
The first quarter of 2025 brought significant advances in gastroenterology, including FDA approvals for mirikizumab and guselkumab, expanding treatment options…
Australian researchers at the University of South Australia, in collaboration with Ferronova, are pioneering a quantum sensor-powered laparoscopic probe that…
Innovative drug delivery systems like nanoparticles, hydrogels, and microgrippers are transforming gastrointestinal treatment—particularly for IBD—by enabling precise, sustained, and targeted…
Neurogastroenterology (NGE), the subspecialty focused on disorders of gut-brain interaction (DGBIs) such as IBS and chronic constipation, faces limited growth…
Teladoc Health has launched a next-generation Cardiometabolic Health Program aimed at preventing and managing diabetes, hypertension, and obesity by addressing…
Once hyped and then humbled, the microbiome therapeutics field is entering a promising new phase, driven by FDA approvals, improved…
mBIOTA Labs announced promising results from the first prospective clinical trial of its elemental diet, mBIOTA Elemental™, showing high effectiveness…
Key takeaways: Neoadjuvant semaglutide showed no benefit in weight loss, diabetes remission or safety in a cohort of patients who…